LUNG TRANSPLANTATION

1. LUNG TRANSPLANTATION ISKANDER AL-GITHMI, M.D., FRCSC, FRCSC (Ts & CDs), FCCP. Assistant Professor of Surgery Division of Cardiothoracic Surgery King Abdulaziz University

2. History: • First human lung transplantation was performed by Dr. James Hardy in June 1963 at the University of Mississippi. • Between 1963 & 1978, 38 lung transplant were done around the world. Two recipients live longer than one month. • Lung and heart-lung transplantation were introduced into clinical practice in 1981 CSA era.

3. History (con’t.) • First successful transplantation in the world was done in 1983 at the University of Toronto. J. Cooper • Over 15,000 lung transplantation have now been performed worldwide. (ISHLT) statistics.

4. What Are Lung Transplantation For?

5. Indications: • Obstructive air way disease (29%) - COPD - Alpha 1 antitrypsin deficiency • Idiopathic pulmonary fibrosis (19%) • Septic pulmonary disease (16%) - Bronchiectasis - cystic fibrosis • Primary pulmonary hypertension (11%)

6. Other Varieties (11%) e.g. - sarcoidosis - lymphangioliomyomatosis (LAM) - eosinophilic granuloma

7. Who are not transplantable?

8. Contra-indications: • Age > 65 years • Active smoking • Poor compliance with the treatment • Severe active infections (HIV, Hepatitis B & C)

9. Con’t. • Active malignancy within the past two years. • Drugs or alcohol abuse. • Dysfunction of major other organs - renal dysfunction - untreatable CAD or LV dysfunction - liver dysfunction

10. Recipient Selective Criteria: • End-stage pulmonary disease with life expectancy < 2 yrs. • Absence of severe extra pulmonary diseases. • Strong motivation towards the idea of lung transplantation. • Severe functional limitation, but potential for rehabilitation. • Excellent psychosocial support.

11. Donor Selective Criteria: • Age < 65 years • No significant lung diseases • Acceptable CXR • PaO2 > 300mm Hg on F102 1.0 and PEEP 5 cm for 5 min. • Bronchoscopy - clear

12. Con’t. • Viral studies are negative (HIV and Hepatitis B & C) • Donor – recipient size matching

13. Medical Conditions – Impact on eligibility for treatment • Symptomatic osteoporosis • Corticosteroid • Nutritional issues • Psychosocial issues • Colonization of air ways with fungi or atypical mycobacteria

14. Guidelines for Timing Referral Chronic obstructive pulmonary disease and a1-antitrypsin deficiency amphysema Postbronchodilator FEV1 < 25% predicted Resting hypoxia: PaO2 < 55 to 60 mm Hg Hypercapnia Secondary pulmonary hypertension Clinical course rapid rate of decline of FEV1 or life-threatening exacerbations Cystic fibrosis Postbronchodilator FEV1 < 30% predicted Resting hypoxia: PaO2 < 55 mm Hg Hypercapnia Clinical course: increasing frequency and severity of exacerbations Idiopathic pulmonary fibrosis VC, TLC < 60-65% predicted Resting hypoxia Secondary pulmonary hypertension Clinical, radiographic, or physiologic progression on medical therapy Primary pulmonary hypertension New York Heart Association functional class III or IV Mean right atrial pressure > 10 mm Hg Mean pulmonary arterial pressure > 50 mm Hg Cardiac index < 2.5 L/min/m2

15. Which transplantation procedure?

17. Living Donor Lobar Lung Transplantation (LDLT)

18. The first living donor lung transplant was reported in 1990. Throughout the world there have been approximately 100 such procedure done to date. • The outcomes for recipients are similar to those who have received lungs from Cadaveric donors. • All living donor lung transplantation have been done utilizing a single lower lobe from each donor which account for about 25% of TLC for each.

19. Recipients Selection for LDLT • Similar as for cadaveric donors. • All candidates are first assessed and listed for cadaveric lung transplantation. • Potential recipient must be large enough to receive the lower lobe of an adult donor – at least the size of an average six year old (90 cm in height).

20. Selection of Potential Donors • Age 18 – 60 years • Blood group compatible with recipient • Of sufficient size • Have normal lungs by clinical, radiographic and physiological assessment.

21. Con’t. • No other significant medical illnesses • No history of hepatitis or HIV • Be willing to undergo complete psychological and psychiatric assessment. • Be willing to undergo complete physical assessment.

22. What Are the Benefits of LDLT?

23. To reduce the number of patient dying while awaiting cadaveric transplantation. • Ability to schedule surgery on a non-urgent basis. • Ability to time transplantation before the recipient becomes too ill.

24. Con’t. • Shorter ischemic times. • Avoidance of hemodynamic instability associated with maintenance of cadaveric donor.

25. Operative goals: • The operation should provide the highest degree of operative safety and the greatest cardio pulmonary rehabilitation.

26. Is the lung transplantation safe?

27. Complications: • Early graft dysfunction – is an acute lung injury that is related to preservation and ischemia reperfusion. - referred to a clinical scenario as pulmonary infiltrate and poor oxygenation. - main consideration are rejection and infection.

28. Con’t. • Airway complications: - Dehiscence - Stenosis - Bronchomalacia

29. Con’t. • Rejection - is the single most important limitation to long-term survival. - Acute rejection * incidence – high * infrequently fatal * the principal risk factor for chronic rejection

30. Why might the lung be prone to rejection?

31. Con’t. • The lung has an extensive vasculature and circulating immune system. • The lung is constantly exposed to extrinsic infectious agents.

32. Con’t. • Infection - is the leading cause of early and late morbidity and mortality. - wide spectrum of pathogens. - bacterial pneumonia and CMV pneumonitis have been the most problematic.

33. Why is the lung allograft so prone to infection?

34. Con’t. • The lung allograft is denervated – cough reflex is depressed. • Mucociliary clearance is depressed. • Lymphatic drainage is disrupted. • Immunisystems are suppressed by anti rejection medications.

35. Con’t. • Lymphoproliferative Disease (PTLD) - the prevalence is 6% - most cases developed in the first year - the risk has been marked by increased in recipient who have had EBV-sero negative before transplantation and have acquired a primary EBV infection afterwards.

36. Con’t. • Outcomes - gauged by survival - quality of life - cost-effectiveness

38. Con’t. • Quality of life - the usual way of measuring the quality of life for lung transplantation is the improvement of pulmonary function test.

40. Con’t. • Cost and Cost-effectiveness Analysis conducted at the University of Washington Medical Center - mean charge was $164,989 - the average charges to post-transplantation care were $16, 628 per month during first 6 months and $5,440 per month during the 2nd month. - Lifetime cost was projected to be $424,853

41. Con’t. • Conclusion: - lung transplantation has expanded rapidly in the last decade. - chronic allograft rejection is a major impediment to long term survival. - progress in immunobiology will likely determine the state of the art.